◆ TICKERBASEOpen interactive view →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksG › GMED

Globus Medical (GMED) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · MEDICAL DEVICES · DATA UPDATED 2026-09-19

Globus Medical (GMED) operates in the MEDICAL DEVICES industry and is headquartered in Audubon, United States with about 6,000 employees. Its market capitalization is roughly $10 billion. In the fiscal year ended 2025-12-31, GMED reported $2.9B in revenue and $538M in net income.

Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally.

Interactive charts & full statements → Open the GMED valuation workbench →

GMED Revenue & Earnings History — Annual Income Statement

Income statementTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-31
Total Revenue$3.1B$2.9B$2.5B$1.6B$1.0B$958M$789M$785M$713M$636M$564M$545M$474M$434M$386M$331M$288M$254M
Gross Profit$2.2B$2.0B$1.5B$1.0B$759M$719M$572M$605M$554M$486M$429M$412M$364M$334M$311M$263M$234M$213M
Gross Margin %68.5%67.4%58.9%65.0%74.2%75.0%72.4%77.1%77.6%76.3%76.1%75.7%76.6%76.9%80.5%79.2%81.3%83.6%
Operating Income (EBIT)$667M$480M$166M$133M$228M$172M$111M$172M$169M$162M$154M$172M$138M$102M$115M$97M$88M$82M
Operating Margin %21.2%16.3%6.6%8.5%22.3%17.9%14.1%21.9%23.8%25.4%27.3%31.6%29.2%23.4%29.7%29.4%30.4%32.2%
Net Income$536M$538M$103M$123M$190M$149M$102M$155M$156M$107M$104M$113M$92M$69M$74M$61M$54M$49M
Net Margin %17.0%18.3%4.1%7.8%18.6%15.6%13.0%19.8%21.9%16.9%18.5%20.7%19.5%15.8%19.1%18.3%18.9%19.2%
EBITDA$730M$474M$347M$305M$265M$178M$229M$219M$205M$193M$196M$160M$121M$133M$116M$106M$97M
Earnings Per Share (EPS)$3.90$3.92$0.75$1.07$1.85$1.44$1.01$1.52$1.54$1.10$1.08$1.17$0.97$0.73$0.80$0.81$0.72$0.54
Shares Outstanding (M)137M138M115M103M104M101M102M101M98M96M96M95M94M92M75M75M91M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GMED Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Total Revenue$790M$760M$826M$769M$745M$598M$657M$626M$630M
Gross Profit$548M$526M$595M$487M$497M$403M$394M$355M$370M
Gross Margin %69.4%69.2%72.0%63.3%66.6%67.3%59.9%56.8%58.7%
Operating Income (EBIT)$196M$164M$172M$135M$76M$97M$60M$48M$50M
Operating Margin %24.8%21.5%20.8%17.6%10.2%16.2%9.2%7.7%7.9%
Net Income$152M$124M$141M$119M$203M$75M$27M$52M$32M
Net Margin %19.2%16.4%17.0%15.5%27.2%12.6%4.0%8.3%5.0%
EBITDA$227M$244M$215M$193M$164M$145M$116M$126M
Earnings Per Share (EPS)$1.10$0.90$1.02$0.88$1.49$0.54$0.19$0.38$0.23
Shares Outstanding (M)138M137M135M136M140M140M138M137M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GMED Free Cash Flow History

Cash flowTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-31
Cash from Operations (CFO)$911M$753M$521M$243M$178M$276M$199M$172M$182M$160M$172M$122M$79M$93M$77M$76M$71M$32M
Capital Expenditures (CapEx)$160M$165M$115M$78M$74M$57M$64M$71M$60M$51M$41M$51M$25M$24M$25M$22M$12M$26M
Free Cash Flow (FCF)$751M$589M$405M$165M$104M$219M$135M$101M$122M$108M$131M$71M$54M$70M$52M$54M$59M$6M
FCF Margin %23.9%20.0%16.1%10.5%10.2%22.9%17.1%12.9%17.1%17.0%23.2%13.1%11.5%16.1%13.4%16.3%20.5%2.4%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GMED Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Cash from Operations (CFO)$210M$202M$249M$250M$78M$177M$210M$204M$54M
Capital Expenditures (CapEx)$33M$40M$56M$31M$52M$41M$17M$42M$28M
Free Cash Flow (FCF)$177M$163M$192M$219M$26M$136M$193M$162M$26M
FCF Margin %22.4%21.4%23.3%28.5%3.5%22.8%29.4%25.8%4.2%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GMED Balance Sheet History

Balance sheet2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-31
Total Assets$5.5B$5.3B$5.3B$5.1B$2.1B$2.0B$1.7B$1.5B$1.3B$1.1B$928M$834M$704M$566M$447M$329M$267M
Cash & Cash Equivalents$508M$526M$784M$467M$150M$193M$239M$196M$140M$119M$67M$60M$82M$90M$212M$143M$112M
Total Liabilities$720M$730M$1.1B$1.1B$230M$216M$173M$130M$115M$111M$96M$119M$118M$94M$61M$47M$38M
Total Debt (Short + Long-Term)$15M$454M$429M$3M$94M$89M$75M$5M$0M$0M$0M$0M$0M$0M$0M$5M
Total Shareholders' Equity$4.8B$4.6B$4.2B$4.0B$1.8B$1.7B$1.5B$1.4B$1.2B$968M$832M$715M$585M$472M$387M$282M$228M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive GMED viewer.

GMED Metric Deep Dives

Other Companies in MEDICAL DEVICES

This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी

← GMECAll “G” companiesGMEU →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.